

Nanogen Inc


GICS Sector Health Care
Sub-Industry Life Sciences Tools & Services

Summary This company, which develops advanced in vitro diagnostics, acquired Epoch Biosciences in late 2004 for about \$97 million.

Key Stock Statistics (Source S&P, Company Reports, Vickers)

Price as of Jun 9, 2006	\$1.87	Dividend Rate/Share	Nil	\$10K Invested 5 Yrs Ago	\$1,989	Total Shares Outstg. (M)	61.0
52-Wk Range	\$4.77-1.80	Trailing 12-Month P/E	NM	Beta	NA	Market Capitalization(B)	\$0.114
Trailing 12-Month EPS	\$-1.99	Tangible Book Val/Share	\$0.51	Yield (%)	Nil	Institutional Ownership (%)	18

Price Performance



Quantitative Evaluations

S&P Earnings & Dividend Rank **NR**

D	C	B-	B	B+	A-	A	A+
---	---	----	---	----	----	---	----

S&P Fair Value Rank **NR**

1	2	3	4	5
---	---	---	---	---

LOWEST HIGHEST

Fair Value Calculation **NA**

Insider Activity **NA**

UNFAVORABLE	NEUTRAL	FAVORABLE
-------------	---------	-----------

Volatility **High**

LOW	AVERAGE	HIGH
-----	---------	------

Technical Evaluation **BEARISH**

Since April, 2006, the technical indicators for NGEN have been BEARISH.

Relative Strength Rank **WEAK**

5

LOWEST = 1 HIGHEST = 99

S&P Analyst **Craig Pratesi**

Operational Review May 25, 2006

Income Statement Analysis & Financial Review

For the first quarter of 2006, total revenues increased 37%, on 75% higher product sales, reflecting the acquisition of Spectral in February 2006, 6.7% higher license fees, and 56% higher revenues from contracts and grants. Total costs and expenses, which significantly exceeded revenues, increased 32%, and the net loss widened to \$12.0 million (\$0.21 a share) from \$8.3 million (\$0.17).

Total revenues more than doubled in 2005, on 69% higher product sales, reflecting acquisitions, and sharply higher license fees and royalty income, reflecting the royalty-bearing licensing agreement with Applied Biosystems for the TaqMan real-time PCR assays. Total costs and expenses, which significantly exceeded revenues, increased sharply due to a \$59 million charge for goodwill impairment. The net loss widened to \$96.5 million (\$1.95 a share, on 54% more shares), from \$38.9 million (\$1.21).

Key Operating Information

Cash, cash equivalents and short-term investments totaled \$32.4 million at March 31, 2006. For the full year 2005, R&D spending totaled \$22.0 million, up from \$18.1 million in 2004. For the 2006 first quarter, R&D spending totaled \$6.3 million, up

from \$4.9 million in the 2005 first quarter.

Recent Developments

On May 1, 2006, NGEN acquired the diagnostics division of Amplimedical S.p.A., a manufacturer of molecular diagnostic products based in Italy, for approximately \$2.5 million in cash and a \$7.5 million promissory note. Prior to the acquisition, Amplimedical was a distributor of NGEN's microarray diagnostic products in Italy and a licensee of certain intellectual property of the company. It also collaborated with NGEN to develop certain multiplexed reagent kits that are sold in Europe.

In February, NGEN acquired the rapid cardiac immunoassay test business of Spectral Diagnostics Inc. for C\$9 million, including C\$5.65 million in cash and C\$3.35 million in common shares. Spectral reported nearly C\$7 million in product revenues during 2005 from the Cardiac STATus tests and i-Lynx readers. Management said the acquisition is part of the company's continuing strategy to acquire complementary product lines and businesses in an attempt to become a leading advanced diagnostics company.

Revenue/Earnings Data

Revenue (Million \$)

	1Q	2Q	3Q	4Q	Year
2006	4.35	--	--	--	--
2005	3.18	3.14	3.17	3.06	12.54
2004	2.16	1.12	1.08	1.01	5.37
2003	1.20	1.69	1.74	2.08	6.71
2002	1.53	1.95	1.55	12.14	17.18
2001	2.94	2.72	3.22	2.30	11.17

Earnings Per Share (\$)

2006	-0.21	--	--	--	--
2005	-0.17	-0.20	-0.18	-1.27	-1.95
2004	-0.20	-0.39	-0.28	-0.31	-1.21
2003	-0.50	-0.32	-0.33	-0.25	-1.38
2002	-0.35	-0.39	-0.38	0.09	-1.02
2001	-0.30	-0.56	-0.33	-0.35	-1.54

Fiscal year ended Dec. 31. Next earnings report expected: Early August

Dividend Data

No cash dividends have been paid.

All of the views expressed in this research report accurately reflect our quantitative research models regarding any and all of the subject securities or issuers. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report. This report is for information purposes and should not be considered a solicitation to buy or sell any security. Neither S&P nor any other party guarantees its accuracy or makes warranties regarding results from its usage. S&P receives compensation from the issuer or an agent thereof for initiating coverage, and for distribution including licensed redistribution of this report, and/or for inclusion in other S&P publications, generally in amounts up to U.S. \$14,175 per year. Redistribution is prohibited without written permission.

Nanogen Inc

Business Summary May 25, 2006

The aim of Nanogen (NGEN) is to provide a higher quality of healthcare through advanced diagnostic products. Its strategy is to assemble the companies, products and knowledge base to become a leading supplier of the technologies and products that will help drive a new era of personalized medicine. NGEN believes that the commercialization of its products and technologies will help bridge the gap between early-stage scientific research and actual clinical practice, and it is developing several product lines that are directly targeting specific markets within the advanced diagnostics field that have significant potential for revenue growth

The company's diagnostic technologies focus on the identification of the nucleic acid sequences, gene variations and gene expressions associated with both genetic conditions and infectious diseases. NGEN believes that its research will contribute to a new healthcare paradigm where disease is diagnosed and understood at the molecular level. It believes that this will lead to the introduction of new therapies, targeted therapeutics and an abundance of new screening tests that will, in turn, shift the focus of medicine to be increasingly proactive as well as being increasingly specific to the individual patient. The company's tests will provide doctors with the information they require to tailor specific therapies to the individual patient. Therefore, it has developed a variety of diagnostic tools for both the relatively simple and complex testing required to render disease specific molecular information accessible to researchers and clinicians.

As a part of its long-term strategy, the company actively and selectively seeks to acquire companies with complementary products and strong intellectual property positions. It also specifically targets companies with existing product lines that complement and add depth to its product portfolio that are or can be turned into cash flow positive entities when integrated into the company. In addition, NGEN is developing an internal infrastructure that allows it to rapidly integrate acquired businesses or product lines.

The company generates product revenues with its advanced diagnostic product lines that are categorized as instrumentation, reagents, custom assays, and test kits. The company's products include real-time polymerase chain reaction (PCR) reagents, the NanoChip400 electronic microarray platform and a line of rapid, point-of-care diagnostic tests.

R&D expenses totaled \$22 million in 2005, \$18 million in 2004 and \$18 million in 2003.

The company plans to grow its business through both the development and launch of new products as well as through the acquisition of products. New products introduced late in 2005 are expected to contribute to revenue in 2006. These products include the second generation NanoChip 400, Analyte Specific Reagents (ASRs) for infectious disease and several real-time ASRs.

As part of its long term strategy, the company has made several acquisitions over the past few years. In February 2006, the company acquired the rapid cardiac immunoassay point-of-care test business of Spectral Diagnostics Inc. This acquisition expanded its menu of products available for point-of-care customers. In July 2005, the company purchased \$350,000 of stock of Pharmacogenetics Diagnostic Laboratory, LLC, a development stage R&D company. The acquisition provides access to services and certain know-how related to pharmacogenetics. In November 2005, the company purchased an additional \$50,000 in stock. In July 2005, NGEN made an equity investment of approximately \$1.5 million in Jurilab LTD, a Finnish company that has assembled a large database of genetic markers by studying the genetic patterns of a founder population in East Finland. In 2004, the company acquired SynX Pharma and Epoch Biosciences. These businesses operate in market niches that are complementary to those of NGEN, and provide the opportunity to broaden the company's product lines in the point-of-care and real-time PCR diagnostic markets.

Customers for the company's instrumentation, ASRs, reagents and custom assays are university and private research institutions, clinical research laboratories and high complexity CLIA certified laboratories. In the U.S., the FDA regulates most diagnostic tests and in vitro reagents marketed as test kits as medical devices. The FDA also considers ASRs to be medical devices. ASRs are exempt from pre-market approval requirements; however, the FDA restricts the sale of these products to those clinical laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988, known as CLIA. All products sold in Europe require CE marking. NGEN's customers in Europe are currently serviced through a distributor network.

Customers of the company's point-of-care products are primarily near patient settings in hospital laboratories and/or emergency rooms. To market and sell to these customers the company is required to receive FDA approval through a "pre-market application". The point-of-care products the company acquired from Spectral Diagnostics in February 2006 have received FDA clearance and are CE marked for distribution in Europe.

Since inception, the company has incurred cumulative net losses which, as of December 31, 2005, total approximately \$311.7 million. NGEN said that its negative cash flow and losses from operations will continue for the foreseeable future.

Corporate Information

Investor Contact

R. Saltmarsh (858-410-4600)

Office

10398 Pacific Center Court, San Diego, CA, USA
92121.

Telephone

858-410-4600.

Email

investor@nanogen.com

Website

http://www.nanogen.com

Officers

Chrmn & CEO

H.C. Birndorf

Pres & COO

D. Ludvigson

SVP, Secy & General Counsel

W.L. Respass

Board of Directors

H. C. Birndorf

W. G. Gerber

S. B. Papadopoulos

D. Schreiber

R. E. Whalen

Domicile

Delaware

Founded

1991

Employees

235

Stockholders

328

Nanogen Inc

Key Stock Statistics

Price as of Jun 9, 2006	\$1.87	Dividend Rate/Share	Nil	\$10K Invested 5 Yrs Ago	\$1,989	Total Shares Outstg. (M)	61.0
52-Wk Range	\$4.77-1.80	Trailing 12-Month P/E	NM	Beta	NA	Market Capitalization(B)	\$0.114
Trailing 12-Month EPS	\$-1.99	Tangible Book Val/Share	\$0.51	Yield (%)	Nil	Institutional Ownership (%)	18

Key Growth Rates and Averages

Past Growth Rate (%)	1 Year	3 Years	5 Years	9 Years
Sales	NM	-11.00	-7.11	15.07
Net Income	-148.01	NM	NM	NM

Ratio Analysis (Annual Avg.)	1 Year	3 Years	5 Years	9 Years
Net Margin (%)	NM	NM	NM	NM
LTD of Capitalization (%)	9.56	3.90	3.17	4.08
Return on Equity (%)	NM	NM	NM	NM

Expanded Ratio Analysis

	2005	2004	2003	2002
Price/Revenue	10.32	44.10	29.86	1.96
Price/EBITDA	NM	NM	NM	NM
Price/Pretax Income	NM	NM	NM	NM
Price/Net Income	NM	NM	NM	NM
Total Shares Outstg (M)	49.6	32.2	22.2	21.7

Figures based on calendar year-end price

Company Financials

Per Share Data (\$) Year Ended Dec. 31	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996
Tangible Book Value	0.51	1.30	1.24	2.45	3.27	4.60	1.95	3.24	NM	8.55
Cash Flow	-1.85	-1.07	-1.18	-0.84	-1.38	-0.79	-1.24	-1.05	-3.40	-4.05
Earnings	-1.95	-1.21	-1.38	-1.02	-1.54	-0.92	-1.39	-1.60	-1.13	-8.04
Dividends	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Payout Ratio	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Prices:High	7.69	14.95	10.29	6.34	13.44	101.94	24.50	12.31	NA	NA
Prices:Low	2.50	3.00	1.00	1.22	3.00	7.69	3.88	2.88	NA	NA
P/E Ratio:High	NM	NM	NM	NM	NM	NM	NM	NM	NA	NA
P/E Ratio:Low	NM	NM	NM	NM	NM	NM	NM	NM	NA	NA

Income Statement Analysis (Million \$)

Revenue	12.5	5.37	6.71	17.2	11.2	11.2	8.12	7.63	3.37	1.64
Operating Income	-34.3	-32.2	-26.2	-22.8	-27.1	-21.0	-24.5	-20.6	-11.8	-7.36
Depreciation	4.87	4.38	4.45	4.09	3.48	2.55	1.71	Nil	0.53	0.35
Interest Expense	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	0.06
Pretax Income	-96.5	-38.9	-32.4	-24.4	-32.5	-18.3	-25.2	-20.9	-11.3	-7.78
Effective Tax Rate	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM
Net Income	-96.5	-38.9	-30.6	-22.2	-32.5	-18.3	-25.2	-20.9	-11.3	-7.78

Balance Sheet & Other Financial Data (Million \$)

Cash	6.19	15.4	8.55	9.42	10.8	55.5	41.0	62.2	19.5	16.8
Current Assets	39.7	57.4	36.9	61.0	79.1	100	43.3	65.2	20.2	17.3
Total Assets	98.1	176	43.8	71.4	90.1	111	50.8	72.7	23.2	19.1
Current Liabilities	9.05	12.4	6.02	7.93	7.55	8.19	9.83	7.48	3.42	2.48
Long Term Debt	7.89	0.61	0.59	1.13	1.76	1.57	2.83	4.18	1.19	0.93
Common Equity	74.6	159	32.8	57.4	74.9	101	38.1	61.1	18.6	15.7
Total Capital	82.5	159	33.4	60.3	76.7	103	41.0	65.2	19.8	16.6
Capital Expenditures	1.32	0.80	1.17	0.14	0.65	0.06	0.03	0.07	0.49	0.11
Cash Flow	-91.6	-34.5	-26.1	-18.2	-29.0	-15.7	-23.5	-19.8	-10.8	-7.43
Current Ratio	4.4	4.6	6.1	7.7	10.5	12.3	4.4	8.7	5.9	7.0
% Long Term Debt of Capitalization	9.6	0.4	1.8	1.9	2.3	1.5	6.9	6.4	6.0	5.6
% Net Income of Revenue	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM
% Return on Assets	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM
% Return on Equity	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM

Data as orig reptd.; bef. results of disc opers/spec. items. Per share data adj. for stk. divs.; EPS diluted. E-Estimated. NA-Not Available. NM-Not Meaningful. NR-Not Ranked. UR-Under Review.

Nanogen Inc

Sub-Industry Outlook

Our outlook for the life sciences tools & services sub-industry is neutral. However, we expect various sectors within the sub-industry to perform better than the industry average and the S&P 1500. The life sciences industry is dependent on pharmaceutical and biotechnology R&D spending and worldwide government funding of academic and research institutions. We see high single digit increases in R&D spending balanced against soft worldwide government funding that may temper overall sales growth. In the U.S., the 2006 National Institutes of Health budget is lower than the 2005 budget, the first decrease in about 30 years. Government funding in France, German and Japan is also decelerating or declining.

Companies within this sub-industry derive revenue from the sale of equipment, consumables, and services. The sale of capital equipment has been sluggish for the past several quarters and we believe that this trend will continue over the near term. We believe companies have been postponing the purchase of high-ticket equipment and extending the life cycle of their current equipment. As a result, we expect manufacturers of these instruments, such as mass spectrometers and chromatographers, to experience sluggish sales. Still, sales typically pick up significantly toward year-end. Overall, we see mid-single digit sales growth for life science equipment.

Purchases of consumables are typically immune from any budget constraints, in our view. Therefore, we believe companies whose revenue base is comprised primarily of consumables will likely grow faster than equipment manufacturers. Consumables also typically carry higher profit margins than instruments and equipment manufacturers are aggressively expanding their product lines to increase their sales of consumables. We see

consumable sales growing in the high single digits.


Companies that provide services to pharmaceutical and biotech firms should see significant growth over the next 12 months, in our opinion. We believe pharmaceutical and biotech firms will increase outsourcing of services over the next several years, as we think it increases efficiency and lowers costs, while minimizing the necessity to expand overseas operations and infrastructure. Also, most emerging biotech firms do not have infrastructure in place and must outsource some services. Beneficiaries of this trend, in our view, will be contract research organizations that provide drug development clinical trial services.

--Jeffrey Loo, CFA

Stock Performance

GICS Sector: Health Care
Sub-Industry: Life Sciences Tools & Services

Based on S&P 1500 Indexes
Month-end Price Performance as of 05/31/06



Sub-Industry Sector S&P 1500

NOTE: All Sector & Sub-Industry information is based on the Global Industry Classification Standard (GICS)

The Sub-Industry was created recently; therefore no historical index data exists yet to display a performance line.

Sub-Industry : Life Sciences Tools & Services Peer Group*: Based on market capitalizations within GICS Sub-Industry

Peer Group	Stock Symbol	Stk.Mkt. Cap. (Mil. \$)	Recent Stock Price	P/E Ratio	12-Mo. Trailing EPS	30-Day Price Chg(%)	1 Year Price Chg(%)	Beta	Yield (%)	Quality Ranking	Ret. on Equity (%)	Pretax Margin (%)	LTD to Cap (%)
Nanogen Inc.	NGEN	114	1.87	NM	-1.99	-25%	-49%	NA	Nil	NR	NM	NM	9.6
Compugen Ltd	CGEN	97	3.49	NM	-0.48	-8%	4%	2.21	Nil	NR	NM	NM	Nil
Gene Logic	GLGC	73	2.28	NM	-1.76	-18%	-29%	2.22	Nil	C	NM	NM	0.1
Genetic Technologies ADS	GENE	102	8.40	NM	-0.60	16%	NA	NA	Nil	NR	NM	NM	6.5
Harvard Bioscience	HBIO	125	4.10	NM	-1.03	-6%	18%	0.97	Nil	NR	2.3	4.1	13.5
Immunicon Corp.	IMMC	139	5.03	NM	-0.96	5%	15%	NA	Nil	NR	NM	NM	6.9
Interleukin Genetics	ILI	138	5.71	NM	-0.29	-18%	81%	1.88	Nil	C	NM	NM	85.5
Life Sciences Research	LSRI	136	10.75	NM	-0.04	7%	-16%	NA	Nil	NR	NM	7.7	102.4
MEDTOX Scientific	MTOX	81	9.91	23	0.44	-1%	50%	0.71	Nil	B-	5.0	5.2	13.9
Medivation Inc	MDV	97	4.35	NM	-0.63	-19%	NA	NA	Nil	NR	NM	NM	Nil
New Brunswick Scient	NBSC	74	8.10	28	0.29	0%	54%	0.58	Nil	B-	5.7	5.3	14.3
Stratagene Corp	STGN	141	6.31	23	0.27	-39%	-28%	NA	Nil	NR	30.2	12.6	14.0
Third Wave Tech	TWTT	120	2.90	NM	-0.54	1%	-25%	1.84	Nil	NR	NM	NM	2.0
VirtualScopics Inc	VSCP	125	5.70	NM	-0.36	36%	NA	NA	Nil	NR	NM	NM	1.0
pSivida Ltd ADS	PSDV	72	4.70	NM	NA	-1%	-30%	NA	Nil	NR	NM	NM	Nil

NA-Not Available NM-Not Meaningful NR-Not Rated. *For Peer Groups with more than 15 companies or stocks, selection of issues is based on market capitalization.

Nanogen Inc

S&P Analyst Research Notes and other Company News

June 12, 2006

Mar. 16, 2006--Nanogen, Inc. (Nasdaq:NGEN) announced that Fisher Scientific International Inc. (NYSE:FSH) agreed to purchase approximately 5.7 million NGEN Common shares at \$2.65 per share. The investment coincides with FSH's purchase of Athena Diagnostics, Inc., a developer and provider of proprietary molecular diagnostic and immunodiagnostic tests and services. NGEN and FSH will collaborate to expand the use of Athena's markers and diagnostic assays. NGEN will use the proceeds from the sale for working capital, acquisitions, and other general corporate purposes.

May 11, 2006

NEW YORK (Standard & Poor's)--May 10, 2006, Nanogen Inc., announced 1Q loss per share of \$0.21 vs. loss of \$0.17.

March 29, 2006

UP 0.63 to 3.33... Receives 510K clearance from FDA to market its StatusFirst CHF NT-prBNP EDTA plasma test to aid in diagnosis of individuals suspected of having congestive heart failure.

March 16, 2006

UP 0.50 to 3.02... Heavy volume... FISHER SCIENTIFIC INTL INC. agrees to buy 5.7 million shares of NGEN at \$2.65 per share.

February 24, 2006

NEW YORK (Standard & Poor's)--Feb 23, 2006, Nanogen Inc., announced 4Q loss per share of \$1.27 vs. loss of \$0.31 and annual loss per share of \$1.95 vs. loss of \$1.21. Results for 2005 include a charge of \$59M from impairment of goodwill.

November 3, 2005

NEW YORK (Standard & Poor's)--Nov 3, 2005, Nanogen Inc., announced 3Q loss per share of \$0.18 vs. loss of \$0.28 and 9 mos. loss per share of \$0.56 vs. loss of \$0.89.

August 3, 2005

NEW YORK (Standard & Poor's)--Aug 2, 2005, Nanogen Inc., announced 2Q loss per share of \$0.20 vs. loss of \$0.39 and 6 mos. loss per share of \$0.38 vs. loss of \$0.61.

May 4, 2005

NEW YORK (Standard & Poor's)--May 3, 2005, Nanogen Inc., announced 1Q loss per share of \$0.17 vs. loss of \$0.20.

March 7, 2005

Jan. 7, 2005--Nanogen, Inc. (Nasdaq:NGEN) announced that it appointed Robert Saltmarsh as chief financial officer. Mr. Saltmarsh has been serving as the company's vice president of corporate development.

February 24, 2005

NEW YORK (Standard & Poor's)--Feb 23, 2005, Nanogen Inc., announced 4Q loss per share of \$0.31 vs. loss of \$0.25 and annual loss per share of \$1.21 vs. loss of \$1.38.

Nanogen Inc

Glossary

Quantitative Evaluations

In contrast to our qualitative STARS recommendations, which are assigned by S&P analysts, the quantitative evaluations described below are derived from proprietary arithmetic models. These computer-driven evaluations may at times contradict an analyst's qualitative assessment of a stock. One primary reason for this is that different measures are used to determine each. For instance, when designating STARS, S&P analysts assess many factors that cannot be reflected in a model, such as risks and opportunities, management changes, recent competitive shifts, patent expiration, litigation risk, etc.

S&P Earnings & Dividend Rank (also known as S&P Quality Rank)

Growth and stability of earnings and dividends are deemed key elements in establishing S&P's earnings and dividend rankings for common stocks, which are designed to encapsulate the nature of this record in a single symbol. It should be noted, however, that the process also takes into consideration certain adjustments and modifications deemed desirable in establishing such rankings. The final score for each stock is measured against a scoring matrix determined by analysis of the scores of a large and representative sample of stocks. The range of scores in the array of this sample has been aligned with the following ladder of rankings:

A+ Highest	B Below Average
A High	B- Lower
A- Above Average	C Lowest
B+ Average	D In Reorganization
NR Not Ranked	

S&P Fair Value Rank

Using S&P's exclusive proprietary quantitative model, stocks are ranked in one of five groups, ranging from Group 5, listing the most undervalued stocks, to Group 1, the most overvalued issues. Group 5 stocks are expected to generally outperform all others. A positive (+) or negative (-) Timing Index is placed next to the Fair Value ranking to further aid the selection process. A stock with a (+) added to the Fair Value Rank simply means that this stock has a somewhat better chance to outperform other stocks with the same Fair Value Rank. A stock with a (-) has a somewhat lesser chance to outperform other stocks with the same Fair Value Rank. The Fair Value rankings imply the following:

- 5-Stock is significantly undervalued
- 4-Stock is moderately undervalued
- 3-Stock is fairly valued
- 2-Stock is modestly overvalued
- 1-Stock is significantly overvalued

S&P Fair Value Calculation

The price at which a stock should trade at, according to S&P's proprietary quantitative model that incorporates both actual and estimated variables (as opposed to only actual variables in the case of S&P Earnings & Dividend Rankings). Relying heavily on a company's actual return on equity, the S&P Fair Value model places a value on a security based on placing a formula-derived price-to-book multiple on a company's consensus earnings per share estimate.

Insider Activity

Gives an insight as to insider sentiment by showing whether directors, officers and key employees who have proprietary information not available to the general public, are buying or selling the company's stock during the most recent six months.

Volatility

Rates the volatility of the stock's price over the past year.

Technical Evaluation

In researching the past market history of prices and trading volume for each company, S&P's computer models apply special technical methods and formulas to identify and project price trends for the stock.

Relative Strength Rank

Shows, on a scale of 1 to 99, how the stock has performed versus all other companies in S&P's universe on a rolling 13-week basis.

Global Industry Classification Standard (GICS)

An industry classification standard, developed by Standard & Poor's in collaboration with Morgan Stanley Capital International (MSCI). GICS is currently comprised of 10 Sectors, 24 Industry Groups, 67 Industries, and 147 Sub-Industries.

Exchange Type

ASE - American Stock Exchange; NNM - Nasdaq National Market; NSC - Nasdaq Smallcap; NYSE - New York Stock Exchange; BB - OTC Bulletin Board; OT - Over-the-Counter; TO - Toronto Stock Exchange.